Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021.

Seppälä E, Veneti L, Starrfelt J, Danielsen AS, Bragstad K, Hungnes O, Taxt AM, Watle SV, Meijerink H

Euro Surveill 26 (35) - [2021-09-00; online 2021-09-04]

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0-27.4) and 64.6% (95% CI: 60.6-68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4-58.3) and 84.4% (95%CI: 81.8-86.5) against the Alpha variant.

Category: Drug Discovery

Category: Genomics & transcriptomics

Category: Vaccines

Type: Journal article

PubMed 34477054

DOI 10.2807/1560-7917.ES.2021.26.35.2100793

Crossref 10.2807/1560-7917.ES.2021.26.35.2100793


Publications 7.1.2